Genera Research Ltd. is a clinical-stage biotechnology company founded in Croatia and is developing recombinant human Bone Morphogenetic Protein (BMP) based products for use in the tissue regeneration and treatment of orthopaedic, spinal, and dental reconstructive procedures.
Core activities of the company are the research and development of biotechnological and biomedical products, the production of recombinant human morphogenetic protein 6 (rhBMP6) and conducting clinical studies. In its portfolio, Genera Research holds over 30 globally protected patents, and it is currently conducting clinical trials the patented innovation "OSTEOGROW" - a family of biological products for bone healing.
The innovation of Ostogrow is in the application of the protein rhBMP6, which enables faster healing of the bone defect by mixing it with the patient's peripheral blood, creating a blood coagulum which is implanted into the bone defect site. The outcome of the application of the drug is successful and lasting and the patient's recovery time is significantly shortened, which increases the patient's quality of life and ability to return to activities. We can proudly say that we “turn blood into bone” which enables practically unlimited quantities of the bone graft for patients without harvesting the patient’s own bone.
The founding team of clinicians and scientists have been involved in the discovery and development of BMP-based products for many years and are poised to bring these efforts to both clinical and commercial success.
- Bone morphogenetic proteins: From discovery to development of a novel autologous bone graft substitute consisting of recombinant human BMP6 delivered in autologous blood coagulum carrier
- Biology of bone morphogenetic protein in bone repair and regeneration: A role for autologous blood coagulum as carrier
- Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction